FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ronald Gust

Research Profile

Chemicals & Drugs

Concepts & Ideas

Anatomy

Disorders

Co-author Network

Publications

TOP 3
Christiane Müller; Ronald Gust; Benjamin N Ma; Andreas Bernkop-Schnürch
Thiopyrazole preactivated chitosan: combining mucoadhesion and drug delivery.
Min Shan; Marcus Weber; Anja Wellner; John A Katzenellenbogen; Alexander Bujotzek; Kathryn E Carlson; Ronald Gust; Rainer Haag
Nonsteroidal bivalent estrogen ligands: an application of the bivalent concept to the estrogen receptor.
Pedro I da S Maia; Hung Huy Nguyen; Silke Bergemann; Victor M Deflon; Ronald Gust; Adelheid Hagenbach; Ulrich Abram
Rhenium mixed-ligand complexes with S,N,S-tridentate thiosemicarbazone/thiosemicarbazide ligands.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ronald Gust (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Christiane Müller; Ronald Gust; Benjamin N Ma; Andreas Bernkop-Schnürch
Thiopyrazole preactivated chitosan: combining mucoadhesion and drug delivery.
Acta biomaterialia 2013;9(5):6585-93.
2013: Min Shan; Marcus Weber; Anja Wellner; John A Katzenellenbogen; Alexander Bujotzek; Kathryn E Carlson; Ronald Gust; Rainer Haag
Nonsteroidal bivalent estrogen ligands: an application of the bivalent concept to the estrogen receptor.
ACS chemical biology 2013;8(4):707-15.
2013: Pedro I da S Maia; Hung Huy Nguyen; Silke Bergemann; Victor M Deflon; Ronald Gust; Adelheid Hagenbach; Ulrich Abram
Rhenium mixed-ligand complexes with S,N,S-tridentate thiosemicarbazone/thiosemicarbazide ligands.
Dalton transactions (Cambridge, England : 2003) 2013;42(14):5111-21.
2013: Wukun Liu; Ronald Gust
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs.
Chemical Society reviews 2013;42(2):755-73.
2012: Sami El Deeb; Benjamin N Ma; Ronald Gust
Development and validation of a LC method for the separation and determination of the anticancer-active Fe(III) (4-methoxy-salophene) using the new second-generation monolith.
Journal of separation science 2012;35(24):3434-8.
2012: Anja Schäfer; Martin Strauss; Anja Wellner; Gerhard Wolber; Andreas Schäfer; Ronald Gust
Influence of chlorine or fluorine substitution on the estrogenic properties of 1-alkyl-2,3,5-tris(4-hydroxyphenyl)-1H-pyrroles.
Journal of medicinal chemistry 2012;55(22):9607-18.
2012: Wukun Liu; Huibin Zhang; Tong Zhang; Jinpei Zhou; Haiyang Zhu; Yanhua Cheng; Ronald Gust
Synthesis and biological evaluation of cyanoguanidine derivatives of loratadine.
Bioorganic & medicinal chemistry letters 2012;22(19):6076-80.
2012: Wukun Liu; Huibin Zhang; Jinpei Zhou; Haiyang Zhu; Yanhua Cheng; Jie Hua; Ronald Gust
Synthesis and in vitro antitumor activity of novel scopoletin derivatives.
Bioorganic & medicinal chemistry letters 2012;22(15):5008-12.
2012: Maria Proetto; Ulrich Abram; Adelheid Hagenbach; Wukun Liu; Ronald Gust
Synthesis, characterization and in vitro antitumour activity of a series of novel platinum(II) complexes bearing Schiff base ligands.
European journal of medicinal chemistry 2012;53():168-75.
2012: Wukun Liu; Xiaohua Chen; Ronald Gust
Synthesis, antitumor, and antibacterial activity of bis[4,5-diarylimidazol-2-ylidene]methane derivatives.
Archiv der Pharmazie 2012;345(7):557-64.
2012: Wukun Liu; Maria Proetto; Ulrich Abram; Kerstin Bensdorf; Adelheid Hagenbach; Ronald Gust
Synthesis, characterization, and in vitro studies of bis[1,3-diethyl-4,5-diarylimidazol-2-ylidene]gold(I/III) complexes.
Journal of medicinal chemistry 2012;55(8):3713-24.
2012: Wukun Liu; Hai Qian; Huibin Zhang; Tong Zhang; Jinpei Zhou; Haiyang Zhu; Wenlong Huang; Ronald Gust
Design and synthesis of thiourea derivatives containing a benzo[5,6]cyclohepta[1,2-b]pyridine moiety as potential antitumor and anti-inflammatory agents.
Bioorganic & medicinal chemistry letters 2012;22(8):2701-4.
2012: Pedro I da S Maia; Silke Bergemann; Victor M Deflon; Ronald Gust; Adelheid Hagenbach; Hung Huy Nguyen; Daniela Ponader; Ulrich Abram
Neutral gold complexes with tridentate SNS thiosemicarbazide ligands.
Inorganic chemistry 2012;51(3):1604-13.
2011: Wukun Liu; Aruljothi Mariappan; Ben Niu; Ulrich Abram; Kerstin Bensdorf; Adelheid Hagenbach; Ronald Gust
Synthesis and biological studies of silver N-heterocyclic carbene complexes derived from 4,5-diarylimidazole.
European journal of medicinal chemistry 2011;46(12):5927-34.
2011: Min Shan; Marcus Weber; Anja Wellner; Oliver Seitz; Frank Abendroth; Alexander Bujotzek; Ronald Gust; Rainer Haag
Conformational analysis of bivalent estrogen receptor ligands: from intramolecular to intermolecular binding.
Chembiochem : a European journal of chemical biology 2011;12(17):2587-98.
2011: Anja Schäfer; Martin Strauss; Anja Wellner; Gerhard Wolber; Ronald Gust
Development of 2,3,5-triaryl-1H-pyrroles as estrogen receptor α selective ligands.
ChemMedChem 2011;6(11):2055-62.
2011: Gerhard Rubner; Anja Wellner; Kerstin Bensdorf; Silke Bergemann; Ronald Gust
Synthesis, characterisation and biological evaluation of copper and silver complexes based on acetylsalicylic acid.
Archiv der Pharmazie 2011;344(10):684-8.
2011: Wukun Liu; Yinglin Liu; Jinpei Zhou; Kerstin Bensdorf; Cancheng Guo; Haoran Liu; Ronald Gust
Licofelone-nitric oxide donors as anticancer agents.
Archiv der Pharmazie 2011;344(8):487-93.
2011: Wukun Liu; Fan Qi; Hai Qian; Anja Wellner; Huibin Zhang; Jinpei Zhou; Kerstin Bensdorf; Xueting Cai; Peng Cao; Wenlong Huang; Zhiyu Li; Ronald Gust
Synthesis and biological activities of 2-amino-thiazole-5-carboxylic acid phenylamide derivatives.
Archiv der Pharmazie 2011;344(7):451-8.
2011: Anja Schäfer; Anja Wellner; Ronald Gust
Synthesis and investigations on the oxidative degradation of C3/C5-alkyl-1,2,4-triarylpyrroles as ligands for the estrogen receptor.
ChemMedChem 2011;6(5):794-803.
2011: Ana Maria Scutaru; Maxi Wenzel; Ronald Gust
Bivalent bendamustine and melphalan derivatives as anticancer agents.
European journal of medicinal chemistry 2011;46(5):1604-15.
2011: Annegret Hille; Tanja Wolf; Petra Schumacher; Ingo Ott; Ronald Gust; Brigitte Kircher
Effects of metal salophene and saldach complexes on lymphoma and leukemia cells.
Archiv der Pharmazie 2011;344(4):217-23.
2011: Sami El Deeb; Mohammed Abu Iriban; Ronald Gust
MEKC as a powerful growing analytical technique.
Electrophoresis 2011;32(1):166-83.
2010: A M Scutaru; M Krüger; M Wenzel; J Richter; Ronald Gust
Investigations on the use of fluorescence dyes for labeling dendrimers: cytotoxicity, accumulation kinetics, and intracellular distribution.
Bioconjugate chemistry 2010;21(12):2222-6.
2010: Gerhard Rubner; Kerstin Bensdorf; Anja Wellner; Silke Bergemann; Ingo Ott; Ronald Gust
[Cyclopentadienyl]metalcarbonyl complexes of acetylsalicylic acid as neo-anticancer agents.
European journal of medicinal chemistry 2010;45(11):5157-63.
2010: Annegret Hille; Ronald Gust
Influence of methoxy groups on the antiproliferative effects of [Fe(III)(salophene-OMe)Cl] complexes.
European journal of medicinal chemistry 2010;45(11):5486-92.
2010: Ana Maria Scutaru; Maxi Wenzel; Heike Scheffler; Gerhard Wolber; Ronald Gust
Optimization of the N-lost drugs melphalan and bendamustine: synthesis and cytotoxicity of a new set of dendrimer-drug conjugates as tumor therapeutic agents.
Bioconjugate chemistry 2010;21(10):1728-43.
2010: Gerhard Rubner; Kerstin Bensdorf; Anja Wellner; Brigitte Kircher; Silke Bergemann; Ingo Ott; Ronald Gust
Synthesis and biological activities of transition metal complexes based on acetylsalicylic acid as neo-anticancer agents.
Journal of medicinal chemistry 2010;53(19):6889-98.
2010: Gilles Berger; Régis Gasper; Delphine Lamoral-Theys; Anja Wellner; Michel Gelbcke; Ronald Gust; Jean Nève; Robert Kiss; Erik Goormaghtigh; Francois Dufrasne
Fourier transform infrared (FTIR) spectroscopy to monitor the cellular impact of newly synthesized platinum derivatives.
International journal of oncology 2010;37(3):679-86.
2010: Luise Richter; Lisa-Marie Munter; Julia Ness; Peter W Hildebrand; Muralidhar Dasari; Stephanie Unterreitmeier; Bruno Bulic; Michael Beyermann; Ronald Gust; Bernd Reif; Sascha Weggen; Dieter Langosch; Gerd Multhaup
Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(33):14597-602.
2010: Matthias Goebel; Gerhard Wolber; Patrick Martk; Bart Staels; Thomas Unger; Ulrich Kintscher; Ronald Gust
Characterization of new PPARgamma agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode.
Bioorganic & medicinal chemistry 2010;18(16):5885-95.
2010: Katrin Splith; Wanning Hu; Ulrich Schatzschneider; Ronald Gust; Ingo Ott; Liliane A Onambele; Aram Prokop; Ines Neundorf
Protease-activatable organometal-Peptide bioconjugates with enhanced cytotoxicity on cancer cells.
Bioconjugate chemistry 2010;21(7):1288-96.
2010: Sandra Dettmann; Katrin Szymanowitz; Anja Wellner; Anke Schiedel; Christa E Müller; Ronald Gust
2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: synthesis and pharmacological evaluation.
Bioorganic & medicinal chemistry 2010;18(14):4905-16.
2010: Timo Kapp; Anja Dullin; Ronald Gust
Platinum(II)-dendrimer conjugates: synthesis and investigations on cytotoxicity, cellular distribution, platinum release, DNA, and protein binding.
Bioconjugate chemistry 2010;21(2):328-37.
2009: Annegret Hille; Ronald Gust
Relationship between anticancer activity and stereochemistry of saldach ligands and their iron(III) complexes.
Archiv der Pharmazie 2009;342(11):625-31.
2009: Matthias Goebel; Bart Staels; Thomas Unger; Ulrich Kintscher; Ronald Gust
Characterization of new PPARgamma agonists: benzimidazole derivatives - the importance of position 2.
ChemMedChem 2009;4(7):1136-42.
2009: Annegret Hille; Ingo Ott; Ana Kitanovic; Igor Kitanovic; Hamed Alborzinia; Elke Lederer; Stefan Wölfl; Nils Metzler-Nolte; Sven Schäfer; William S Sheldrick; Caroline Bischof; Ulrich Schatzschneider; Ronald Gust
[N,N'-Bis(salicylidene)-1,2-phenylenediamine]metal complexes with cell death promoting properties.
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 2009;14(5):711-25.
2009: Zhenlin Bai; Ronald Gust
Breast cancer, estrogen receptor and ligands.
Archiv der Pharmazie 2009;342(3):133-49.
2009: Matthias Goebel; Markus Clemenz; Bart Staels; Thomas Unger; Ulrich Kintscher; Ronald Gust
Characterization of new PPARgamma agonists: analysis of telmisartan's structural components.
ChemMedChem 2009;4(3):445-56.
2009: Ingo Ott; Brigitte Kircher; Christoph P Bagowski; Danielle H W Vlecken; Elisabeth B Ott; Joanna Will; Kerstin Bensdorf; William S Sheldrick; Ronald Gust
Modulation of the biological properties of aspirin by formation of a bioorganometallic derivative.
Angewandte Chemie (International ed. in English) 2009;48(6):1160-3.
2008: Burkhard Kleuser; Daniela Malek; Ronald Gust; Heinz H Pertz; Henrik Potteck
17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30.
Molecular pharmacology 2008;74(6):1533-43.
2008: Miriam Schlenk; Ingo Ott; Ronald Gust
Cobalt-alkyne complexes with imidazoline ligands as estrogenic carriers: synthesis and pharmacological investigations.
Journal of medicinal chemistry 2008;51(22):7318-22.
2008: Ingo Ott; Michael Scharwitz; Heike Scheffler; William S Sheldrick; Ronald Gust
Atomic absorption spectrometric determination of the iridium content in tumor cells exposed to an iridium metallodrug.
Journal of pharmaceutical and biomedical analysis 2008;47(4-5):938-42.
2008: Timo Kapp; Peter Francke; Ronald Gust
Investigations on surface modified dendrimers: enzymatic hydrolysis and uptake into MCF-7 breast cancer cells.
ChemMedChem 2008;3(4):635-41.
2007: Ingo Ott; Heike Scheffler; Ronald Gust
Development of a method for the quantification of the molar gold concentration in tumour cells exposed to gold-containing drugs.
ChemMedChem 2007;2(5):702-7.
2007: Alkje Moritz; Ronald Gust; Heinz H Pertz
Characterization of the relaxant response to N,N'-dipropyl-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine in porcine coronary arteries.
The Journal of pharmacology and experimental therapeutics 2007;321(2):699-706.
2007: Thomas Wiglenda; Ronald Gust
Structure-activity relationship study to understand the estrogen receptor-dependent gene activation of aryl- and alkyl-substituted 1H-imidazoles.
Journal of medicinal chemistry 2007;50(7):1475-84.
2007: Ingo Ott; Ronald Gust
Non platinum metal complexes as anti-cancer drugs.
Archiv der Pharmazie 2007;340(3):117-26.
2007: Sabine Schertl; Rolf W Hartmann; Christine Batzl-Hartmann; Thilo Spruss; Anton Maucher; Erwin von Angerer; Claus D Schiller; Martin R Schneider; Ronald Gust; Helmut Schönenberger
Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies.
Journal of cancer research and clinical oncology 2007;133(3):153-67.
2007: Christian Banekovich; Ingo Ott; Thao Koch; Barbara Matuszczak; Ronald Gust
Synthesis and biological activities of novel dexibuprofen tetraacetylriboflavin conjugates.
Bioorganic & medicinal chemistry letters 2007;17(3):683-7.
2007: Ingo Ott; Ronald Gust
Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment.
Anti-cancer agents in medicinal chemistry 2007;7(1):95-110.
2006: Ingo Ott; Angelika Abraham; Petra Schumacher; Hashem Shorafa; Guenther Gastl; Ronald Gust; Brigitte Kircher
Synergistic and additive antiproliferative effects on human leukemia cell lines induced by combining acetylenehexacarbonyldicobalt complexes with the tyrosine kinase inhibitor imatinib.
Journal of inorganic biochemistry 2006;100(11):1903-6.
2006: Alkje Moritz; Oliver A Radtke; Ronald Gust; Erika Glusa; Heinz H Pertz
Characterisation of the relaxant response to raloxifene in porcine coronary arteries.
European journal of pharmacology 2006;545(2-3):153-60.
2006: Anja Dullin; Francois Dufrasne; Michael Gelbcke; Ronald Gust
Synthesis and cytotoxicity of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)-3-methylbutane]platinum(II) complexes.
ChemMedChem 2006;1(6):644-53.
2006: Timo Kapp; Stefanie Müller; Ronald Gust
Dinuclear alkylamine platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II): influence of endocytosis and copper and organic cation transport systems on cellular uptake.
ChemMedChem 2006;1(5):560-4.
2006: Daniela Malek; Ronald Gust; Burkhard Kleuser
17-Beta-estradiol inhibits transforming-growth-factor-beta-induced MCF-7 cell migration by Smad3-repression.
European journal of pharmacology 2006;534(1-3):39-47.
2006: Timo Kapp; Anja Dullin; Ronald Gust
Mono- and polynuclear [alkylamine]platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II): synthesis and investigations on cytotoxicity, cellular distribution, and DNA and protein binding.
Journal of medicinal chemistry 2006;49(3):1182-90.
2006: Ingo Ott; Ronald Gust
[Special qualities of inorganic cytostatics. Medicinal chemistry of platinum complexes].
Pharmazie in unserer Zeit 2006;35(2):124-33.
2005: Ronald Gust; Karlheinz Niebler; Helmut Schönenberger
[N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
Journal of medicinal chemistry 2005;48(23):7132-44.
2005: Thomas Wiglenda; Ingo Ott; Brigitte Kircher; Petra Schumacher; Daniela Schuster; Thierry Langer; Ronald Gust
Synthesis and pharmacological evaluation of 1H-imidazoles as ligands for the estrogen receptor and cytotoxic inhibitors of the cyclooxygenase.
Journal of medicinal chemistry 2005;48(20):6516-21.
2005: Ingo Ott; Thao Koch; Hashem Shorafa; Zhenlin Bai; Daniel Poeckel; Dieter Steinhilber; Ronald Gust
Synthesis, cytotoxicity, cellular uptake and influence on eicosanoid metabolism of cobalt-alkyne modified fructoses in comparison to auranofin and the cytotoxic COX inhibitor Co-ASS.
Organic & biomolecular chemistry 2005;3(12):2282-6.
2005: Ingo Ott; Ronald Gust
Stability, protein binding and thiol interaction studies on [2-acetoxy-(2-propynyl)benzoate]hexacarbonyldicobalt.
Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine 2005;18(2):171-7.
2005: Ingo Ott; Kathrin Schmidt; Brigitte Kircher; Petra Schumacher; Thomas Wiglenda; Ronald Gust
Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action.
Journal of medicinal chemistry 2005;48(2):622-9.
2005: Moriz von Rauch; Sandra Busch; Ronald Gust
Investigations on the effects of basic side chains on the hormonal profile of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines.
Journal of medicinal chemistry 2005;48(2):466-74.
2004: Peter M Kekenes-Huskey; Ingo Muegge; Moriz von Rauch; Ronald Gust; Ernst-Walter Knapp
A molecular docking study of estrogenically active compounds with 1,2-diarylethane and 1,2-diarylethene pharmacophores.
Bioorganic & medicinal chemistry 2004;12(24):6527-37.
2004: Anja Dullin; Francois Dufrasne; Michael Gelbcke; Ronald Gust
Enantiomerically pure [1, 2-diamino-1-(4-fluorophenyl)butane]platinum(II) complexes: synthesis and antitumor activity against MCF-7 and MDA-MB 231 breast cancer and LnCaP/FGC prostate cancer cell lines.
Archiv der Pharmazie 2004;337(12):654-67.
2004: Ronald Gust; Ingo Ott; Diana Posselt; Klaus Sommer
Development of cobalt(3,4-diarylsalen) complexes as tumor therapeutics.
Journal of medicinal chemistry 2004;47(24):5837-46.
2004: Sabine Schertl; Rolf W Hartmann; Christine Batzl-Hartmann; Günther Bernhardt; Thilo Spruss; Karin Beckenlehner; Marion Koch; Rudolf Krauser; Richard Schlemmer; Ronald Gust; Helmut Schönenberger
[1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action II: contribution of drug inactivation, cellular drug uptake and sterical factors in the drug-target interaction to the antitumor activity.
Archiv der Pharmazie 2004;337(6):349-59.
2004: Sabine Schertl; Rolf W Hartmann; Christine Batzl-Hartmann; Günther Bernhardt; Thilo Spruss; Karin Beckenlehner; Marion Koch; Rudolf Krauser; Richard Schlemmer; Ronald Gust; Helmut Schönenberger
[1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level.
Archiv der Pharmazie 2004;337(6):335-48.
2004: Sabine Fuchs; Timo Kapp; Harald Otto; Torsten Schöneberg; Peter Franke; Ronald Gust; A Dieter Schlüter
A surface-modified dendrimer set for potential application as drug delivery vehicles: synthesis, in vitro toxicity, and intracellular localization.
Chemistry (Weinheim an der Bergstrasse, Germany) 2004;10(5):1167-92.
2004: Ingo Ott; Brigitte Kircher; Ronald Gust
Investigations on the effects of cobalt-alkyne complexes on leukemia and lymphoma cells: cytotoxicity and cellular uptake.
Journal of inorganic biochemistry 2004;98(3):485-9.
2004: Moriz von Rauch; Miriam Schlenk; Ronald Gust
Effects of C2-alkylation, N-alkylation, and N,N'-dialkylation on the stability and estrogen receptor interaction of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines.
Journal of medicinal chemistry 2004;47(4):915-27.
2003: Ronald Gust; Veronika Lubczyk
Structure activity relationship studies on C2 side chain substituted 1,1-bis(4-methoxyphenyl)-2-phenylalkenes and 1,1,2-tris(4-methoxyphenyl)alkenes.
The Journal of steroid biochemistry and molecular biology 2003;87(1):75-83.
2003: Ronald Gust; Sandra Busch; Roland Keilitz; Kathrin Schmidt; Moriz von Rauch
Invesgations [correction investigations] on the influence of halide substituents on the estrogen receptor interaction of 2, 4, 5-tris(4-hydroxyphenyl)imidazoles.
Archiv der Pharmazie 2003;336(10):456-65.
2003: Ronald Gust; Veronika Lubczyk
Investigations on the influence of terminal groups at the C2-propyl side chain of 1,1-bis(4-hydroxyphenyl)-2-phenylpent-1-ene and 1,1,2-tris(4-hydroxyphenyl)pent-1-ene on the estrogen receptor binding and the estrogenic/anti-estrogenic properties.
The Journal of steroid biochemistry and molecular biology 2003;86(1):57-70.
2003: Veronika Lubczyk; Helmut Bachmann; Ronald Gust
Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
Journal of medicinal chemistry 2003;46(8):1484-91.
2002: Ronald Gust; Roland Keilitz; Kathrin Schmidt; Moriz von Rauch
Synthesis, structural evaluation, and estrogen receptor interaction of 4,5-bis(4-hydroxyphenyl)imidazoles.
Archiv der Pharmazie 2002;335(10):463-71.
2002: Veronika Lubczyk; Helmut Bachmann; Ronald Gust
Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
Journal of medicinal chemistry 2002;45(24):5358-64.
2002: Ronald Gust; Roland Keilitz; Kathrin Schmidt; Moriz von Rauch
(4R,5S)/(4S,5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines: ligands for the estrogen receptor with a novel binding mode.
Journal of medicinal chemistry 2002;45(16):3356-65.
2002: Ronald Gust; Roland Keilitz; Kathrin Schmidt
Synthesis, structural evaluation, and estrogen receptor interaction of 2,3-diarylpiperazines.
Journal of medicinal chemistry 2002;45(11):2325-37.
2002: Francois Dufrasne; Michael Gelbcke; Beate Schnurr; Ronald Gust
Synthesis and antitumor activity of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)propane]dichloroplatinum(II) complexes.
Archiv der Pharmazie 2002;335(5):229-39.
2001: Ronald Gust; Roland Keilitz; Kathrin Schmidt
Investigations of new lead structures for the design of selective estrogen receptor modulators.
Journal of medicinal chemistry 2001;44(12):1963-70.
2001: Sabine Schertl; Rolf W Hartmann; Christine Batzl-Hartmann; Richard Schlemmer; Thilo Spruss; Günther Bernhardt; Ronald Gust; Helmut Schönenberger
1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic properties.
Archiv der Pharmazie 2001;334(4):125-37.
2001: Ronald Gust; Veronika Lubczyk; K Schmidt; U Shihada
Synthesis, conformational studies, and investigations on the estrogen receptor binding of [R/S-1-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]platinum(II) complexes.
Archiv der Pharmazie 2001;334(3):93-100.
2000: Ronald Gust; M Faderl; Helmut Schönenberger
[Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
Journal of cancer research and clinical oncology 2000;126(11):647-54.
1999: Kathrin Schmidt; Ronald Gust; M Jung
Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells.
Archiv der Pharmazie 1999;332(10):353-7.
1999: Ronald Gust; Roland Keilitz; Rudolf Krauser; Kathrin Schmidt; Beate Schnurr
Structure activity studies on leaving group derivatives of [meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] platinum(II).
Archiv der Pharmazie 1999;332(8):261-70.
1999: Günther Bernhardt; Marion Koch; Thilo Spruss; Ronald Gust; Rudolf Krauser; Richard Schlemmer; M Hollstein; F Lux; Helmut Schönenberger
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] sulfatoplatinum(II)--pharmacokinetic studies.
Archiv der Pharmazie 1999;332(6):195-200.
1998: Ronald Gust; Beate Schnurr; Rudolf Krauser; Günther Bernhardt; M Koch; B Schmid; E Hummel; Helmut Schönenberger
Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)-ethylenediamine][cyclobutane-1,1- dicarboxylato]platinum(II), a novel, highly active carboplatin derivative.
Journal of cancer research and clinical oncology 1998;124(11):585-97.
1998: Ronald Gust; Rudolf Krauser; B Schmid; Helmut Schönenberger
Synthesis and antitumor activity of [1,2-bis(4-fluorophenyl)ethylenediamine][dicarboxylato]platinum(II) complexes.
Archiv der Pharmazie 1998;331(1):27-35.
1995: Ronald Gust; Günther Bernhardt; Thilo Spruss; Rudolf Krauser; M Koch; Helmut Schönenberger; K H Bauer; S Schertl; Z Lu
Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activity.
Archiv der Pharmazie 1995;328(9):645-53.
1995: Ronald Gust; Helmut Schönenberger
Third generation antitumor platinum(II) complexes of the [1-(fluoro/difluorophenyl)-2-phenylethylenediamine]platinum(II) type.
Archiv der Pharmazie 1995;328(7-8):595-603.
1995: Ronald Gust; K Niebler; Helmut Schönenberger
Investigation of the configurational and conformational influences on the hormonal activity of 1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines and of their platinum(II) complexes. 1. Synthesis, estradiol receptor affinity, and estrogenic activity of diastereomeric [N-alkyl- and N,N'-dialkyl-1,2- bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes.
Journal of medicinal chemistry 1995;38(12):2070-9.
1995: Ronald Gust; J Karl; M Faderl; Helmut Schönenberger
Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
Archiv der Pharmazie 1995;328(5):457-63.
1994: Ronald Gust; Helmut Schönenberger
Investigation of the conformational influences on the estrogenic activity of 1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines and of their platinum(II) complexes, II: Synthesis and studies on the estrogenic activity of cis- and trans[bis(2,6-dichloro-4-hydroxybenzylamine)]dihaloplatinum(II)-c omplexes.
Archiv der Pharmazie 1994;327(12):763-9.
1994: Ronald Gust
Aqua[1,1-bis(4-hydroxyphenyl)-1,2-diamino-2-phenylethane]- sulfatoplatinum(II), a new compound for the treatment of the mammary carcinoma.
Archiv der Pharmazie 1994;327(1):49-54.
1993: Ronald Gust; Helmut Schönenberger; U Klement; K J Range
Aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2- phenylethylenediamine]sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring, II: Correlation of molecular structure and estrogenic activity of breast and prostate cancer inhibiting. [erythro-1-(2,6-dichloro-4-hydroxyphenyl)-2-(2-halo-4- hydroxyphenyl)ethylenediamine]platinum(II) complexes.
Archiv der Pharmazie 1993;326(12):967-76.
1993: Ronald Gust; Helmut Schönenberger
Mammary tumor inhibiting [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, III: Relationship between structure and estrogenic activity of the diamine ligands, their sulfatoplatinum(II) and diiodoplatinum(II) complexes.
Archiv der Pharmazie 1993;326(7):405-13.
1993: Thilo Spruss; S Schertl; M R Schneider; Ronald Gust; K Bauer; Helmut Schönenberger
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.
Journal of cancer research and clinical oncology 1993;119(12):707-16.
1992: Günther Bernhardt; R Müller; Ronald Gust; H Reile; C Keller; Thilo Spruss; Helmut Schönenberger
Dichloro-[1-(hydroxyphenyl)-2-phenylethylenediamine]platinum(II) complexes: testing on the human ovarian cancer cell lines NIH: OVCAR3 and SK OV 3.
Archiv der Pharmazie 1992;325(2):93-9.
1992: S Schertl; Ronald Gust; R Müller; Thilo Spruss; Helmut Schönenberger
Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
Archiv der Pharmazie 1992;325(2):113-8.
1992: Günther Bernhardt; Ronald Gust; H Reile; H D vom Orde; R Müller; C Keller; Thilo Spruss; Helmut Schönenberger; T Burgemeister; A Mannschreck
[1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line.
Journal of cancer research and clinical oncology 1992;118(3):209-15.
1992: Günther Bernhardt; Ronald Gust; H Reile; H D vom Orde; R Müller; C Keller; Thilo Spruss; Helmut Schönenberger; T Burgemeister; A Mannschreck
[1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.
Journal of cancer research and clinical oncology 1992;118(3):201-8.
1991: H Reile; Thilo Spruss; Günther Bernhardt; R Müller; Ronald Gust; Helmut Schönenberger
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part IV: Biological evaluation--in vivo studies on the P 388 leukemia.
Archiv der Pharmazie 1991;324(7):405-9.
1990: Ronald Gust; T Burgemeister; A Mannschreck; Helmut Schönenberger
Aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2- phenylethylenediamine](sulfato)platinum-(II) complexes with variable substituents in the 2-phenyl ring. 1. Synthesis and antitumor and estrogenic properties.
Journal of medicinal chemistry 1990;33(9):2535-44.
1990: Patrick J Bednarski; Ronald Gust; Thilo Spruss; N Knebel; A Otto; M Farbel; R Koop; Eggehard Holler; Erwin von Angerer; Helmut Schönenberger
Platinum compounds with estrogen receptor affinity.
Cancer treatment reviews 1990;17(2-3):221-31.
1990: H Reile; Thilo Spruss; R Müller; Ronald Gust; Günther Bernhardt; Helmut Schönenberger; J Engel
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes, III: Evaluation of the mammary tumor inhibiting properties.
Archiv der Pharmazie 1990;323(5):301-6.
1990: H Reile; R Müller; Ronald Gust; R Laske; W Krischke; Günther Bernhardt; Thilo Spruss; M Jennerwein; J Engel; S Seeber
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part II: Biological evaluation-in vitro studies on the P 388 D1 leukemia cell line.
Archiv der Pharmazie 1990;323(3):133-40.
1990: Thilo Spruss; Ronald Gust; R Müller; J Engel; Helmut Schönenberger
Mammary tumor inhibiting properties of the (S,S)-configurated [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complex.
Archiv der Pharmazie 1990;323(2):99-102.
1990: R Müller; Ronald Gust; Günther Bernhardt; C Keller; Helmut Schönenberger; S Seeber; R Osieka; Alan Eastman; M Jennerwein
[DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer.
Journal of cancer research and clinical oncology 1990;116(3):237-44.
1990: H D vom Orde; H Reile; R Müller; Ronald Gust; Günther Bernhardt; Thilo Spruss; Helmut Schönenberger; T Burgemeister; A Mannschreck
Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes.
Journal of cancer research and clinical oncology 1990;116(5):434-8.
1989: M Jennerwein; Ronald Gust; R Müller; Helmut Schönenberger; J Engel; M R Berger; D Schmähl; S Seeber; R Osieka; G Atassi
Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties.
Archiv der Pharmazie 1989;322(2):67-73.
1989: M Jennerwein; Ronald Gust; R Müller; Helmut Schönenberger; J Engel; M R Berger; D Schmähl; S Seeber; R Osieka; G Atassi
Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis.
Archiv der Pharmazie 1989;322(1):25-9.
1988: M Jennerwein; B Wappes; Ronald Gust; Helmut Schönenberger; J Engel; S Seeber; R Osieka
Influence of ring substituents on the antitumor effect of dichloro(1,2-diphenylethylenediamine)platinum(II) complexes.
Journal of cancer research and clinical oncology 1988;114(4):347-58.
1988: J Karl; Ronald Gust; Thilo Spruss; M R Schneider; Helmut Schönenberger; J Engel; K H Wrobel; F Lux; S T Haeberlin
Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
Journal of medicinal chemistry 1988;31(1):72-83.